A previous study performed a meta-analysis of IDH1 and IDH2 mutations from 55 different studies with 9,487 glioma tumors found both mutations were independently and statistically significantly associated with better OS and PFS of glioma patients (32). The gene discussed is IDH2; the disease is central nervous system cancer.